Advertisement
U.S. markets closed

XBiotech Inc. (XBIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
7.57+0.02 (+0.26%)
At close: 04:00PM EDT
7.57 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close7.55
Open7.48
Bid0.00 x 0
Ask0.00 x 0
Day's Range7.45 - 7.60
52 Week Range3.51 - 9.96
Volume18,823
Avg. Volume50,568
Market Cap230.606M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateNov 07, 2024 - Nov 11, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 15, 2021
1y Target EstN/A
  • Associated Press Finance

    XBiotech: Q2 Earnings Snapshot

    AUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Monday reported a loss of $13 million in its second quarter. The Austin, Texas-based company said it had a loss of 43 cents per share.

  • GlobeNewswire

    XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

    Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen